Abstract:
PROBLEM TO BE SOLVED: To provide a knockout animal on TAAR1 function. SOLUTION: This vector structure containing a genome sequence homologous to upstream and downstream regions adjacent to a single code exon of TAAR1 gene, one or more selected marker genes, and optionally a reporter gene, and its use. Additionally, a TAAR1 knockout animal and its use. COPYRIGHT: (C)2007,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a finger print sequence which is specific and selective to trace amine-associated receptors (TAAR) forming a subfamily of G protein-coupled receptors. SOLUTION: The present invention provides a finger print sequence which is specific and selective to a trace amine-associated receptor (TAAR) forming a subfamily of the G protein-coupled receptors and provides a new human polypeptides identified as members of the family, nucleic acids encoding the polypeptides and vectors and host cells comprising new family members and further provides a method for identifying TAARs. COPYRIGHT: (C)2006,JPO&NCIPI
Abstract:
PROBLEM TO BE SOLVED: To provide a new trace amine-associated substance receptor of mouse and its use. SOLUTION: The invention provides a finger print sequence specifically selective to a trace amine-associated substance receptor (TAAR) forming a subfamily of a G-protein conjugate receptor. The invention further provides a new mouse polypeptide identified as a member of the family, a nucleic acid encoding the polypeptide, a vector and a host cell containing the new family member and a method for identifying TAAR. COPYRIGHT: (C)2006,JPO&NCIPI
Abstract:
PROBLEM TO BE SOLVED: To provide a TAAR1 transgenic animal. SOLUTION: This invention relates to a genetic construct containing a DNA encoding TAAR1, its use in TAAR1 for making an animal which is transgenic for TAAR1, a transgenic animal containing a transgenic DNA encoding TAAR1, its use, and a method for making these animals. COPYRIGHT: (C)2007,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a TAAR (trace amine associated receptor) of a chimpanzee, forming a subfamily of a G-protein coupled receptor. SOLUTION: The new TAAR polypeptide of the chimpanzee is identified as a member of the subfamily of the G-protein coupled receptor, and a fingerprint sequence specific and selective for the TAAR polypeptide is provided. Furthermore, a nucleic acid encoding the TAAR polypeptide and a vector and a host cell containing the family member are provided. In addition, a method for identifying the TAAR of the chimpanzee is provided. COPYRIGHT: (C)2006,JPO&NCIPI
Abstract:
본발명은하기화학식 I의화합물, 또는이의약학적으로허용되는염 또는산 부가염, 라세미체혼합물, 또는이의상응하는거울상이성질체및/또는광학이성질체및/또는입체이성질체에관한것이다: [화학식 I]상기식에서, R은저급알킬이고; R는페닐또는피리딘일이고, 여기서피리딘일기 내의 N 원자는상이한위치에존재할수 있고; n은 0, 1 또는 2이고; V 및 U는서로독립적으로 O 또는 CH이고, 여기서 V 및 U는동시에 O일수 없고; L은하기로부터선택되는 5원또는 6원헤테로아릴기이다:. 상기화합물은파킨슨병, 불안, 구토, 강박장애, 자폐증, 신경보호, 암, 우울증및 2형당뇨병의치료에사용될수 있다.
Abstract:
The present invention provides a fingerprint sequence which is specific and selective for rat trace amine associated receptors (TAAR) forming a subfamily of G protein coupled receptors. The invention also provides the novel rat polypeptides identified as members of this family, nucleic acids encoding said polypeptides, and vectors and host cells comprising the novel family members. In addition, the invention provides methods of identifying rat TAARs.
Abstract:
The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competitive mGluR5 allosteric modulator which has a shift factor measured at 10 uM glutamate concentration below 3.0.
Abstract:
La présente invention concerne des dérivés d'éthynyle de formule (i) dans laquelle y est un groupe n ou ch, r1 est un groupe fluoro ou chloro, r2 est un groupe hydrogène ou méthyle ou leur sel d'addition aux acides pharmaceutiquement acceptable, leur mélange racémique, ou leur énantiomère et/ou isomère optique et/ou stéréoisomère correspondant. Il a été découvert avec surprise que les composés de formule générale i sont des antagonistes des récepteurs métabotropes au glutamate (modulateurs allostériques négatifs) destinés à être utilisés dans le traitement de l'anxiété et de la douleur, de la dépression, du syndrome de l'x fragile, des troubles du spectre autistique, de la maladie de parkinson et de la maladie du reflux gastro-oesophagien).